[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fS620srD3IbfDPRGrkRIQID-6wIuyuc-_mLCbU6_e__Y":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":82,"rows":89},"Mirum Pharmaceuticals, Inc.",[4],37,false,11,12,2516,15,1,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Alagille Syndrome",10,{"name":18,"count":19},"Progressive Familial Intrahepatic Cholestasis (PFIC)",4,{"name":21,"count":22},"Chronic Hepatitis D Infection",3,{"name":24,"count":22},"Progressive Familial Intrahepatic Cholestasis",{"name":26,"count":22},"Non-Alcoholic Steatohepatitis",{"name":28,"count":29},"Primary Biliary Cirrhosis",2,{"name":31,"count":29},"PBC",{"name":33,"count":29},"Cholestatic Liver Disease",[35,40,45,50,54,58,63,68,73,77],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04663308","A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)","2026-06","Volixibat",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT07298330","A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)","2026-08","Brelovitug 300 mg",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT06553768","Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)","2026-10","Maralixibat",{"nctId":51,"briefTitle":52,"date":53,"intervention":39},"NCT05050136","A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis","2027-04",{"nctId":55,"briefTitle":56,"date":57,"intervention":44},"NCT07200908","A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)","2027-06-30",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT07454837","Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide","2027-08-31","Brelovitug",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT07209462","Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)","2027-10","Low dose of MRM-3379",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT06193928","Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)","2028-09-20","Livmarli",{"nctId":74,"briefTitle":75,"date":76,"intervention":44},"NCT06907290","A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection","2029-05",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07290257","Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)","2030-09-22","Livmarli Oral Product",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,113,152,174,196,219,237,255,352,395,419,437,455,473,499,520,556,585,603,621,639,668,763,803],{"intervention":81,"totalTrials":12,"cells":91},{"EARLY_PHASE1":92,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":111},{"trials":93,"activeCount":94},[],0,{"trials":96,"activeCount":94},[],{"trials":98,"activeCount":94},[],{"trials":100,"activeCount":94},[],{"trials":102,"activeCount":12,"soonestReadout":80},[103],{"nctId":78,"briefTitle":79,"status":104,"phases":105,"primaryCompletion":80,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":110},"RECRUITING",[87],"2030-12-22","2025-09-25",100,[15],[81],{"trials":112,"activeCount":94},[],{"intervention":44,"totalTrials":22,"cells":114},{"EARLY_PHASE1":115,"PHASE1":117,"PHASE2":119,"PHASE3":121,"PHASE4":148,"NA":150},{"trials":116,"activeCount":94},[],{"trials":118,"activeCount":94},[],{"trials":120,"activeCount":94},[],{"trials":122,"activeCount":22,"soonestReadout":43},[123,132,140],{"nctId":41,"briefTitle":42,"status":104,"phases":124,"primaryCompletion":43,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":129},[86],"2029-01","2026-01-14",80,[21],[44,130,131],"Brelovitug 900 mg","Delayed Treatment with Brelovitug 300mg",{"nctId":55,"briefTitle":56,"status":104,"phases":133,"primaryCompletion":57,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":138},[86],"2029-09-30","2025-08-27",172,[21],[44,139],"Bulevirtide 2 mg and Brelovitug - 300 mg",{"nctId":74,"briefTitle":75,"status":141,"phases":142,"primaryCompletion":76,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},"ACTIVE_NOT_RECRUITING",[85,86],"2029-09","2025-03-25",150,[21],[44,130,131],{"trials":149,"activeCount":94},[],{"trials":151,"activeCount":94},[],{"intervention":130,"totalTrials":29,"cells":153},{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":170,"NA":172},{"trials":155,"activeCount":94},[],{"trials":157,"activeCount":94},[],{"trials":159,"activeCount":94},[],{"trials":161,"activeCount":29,"soonestReadout":43},[162,166],{"nctId":41,"briefTitle":42,"status":104,"phases":163,"primaryCompletion":43,"completion":125,"start":126,"enrollment":127,"conditions":164,"interventions":165},[86],[21],[44,130,131],{"nctId":74,"briefTitle":75,"status":141,"phases":167,"primaryCompletion":76,"completion":143,"start":144,"enrollment":145,"conditions":168,"interventions":169},[85,86],[21],[44,130,131],{"trials":171,"activeCount":94},[],{"trials":173,"activeCount":94},[],{"intervention":131,"totalTrials":29,"cells":175},{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":192,"NA":194},{"trials":177,"activeCount":94},[],{"trials":179,"activeCount":94},[],{"trials":181,"activeCount":94},[],{"trials":183,"activeCount":29,"soonestReadout":43},[184,188],{"nctId":41,"briefTitle":42,"status":104,"phases":185,"primaryCompletion":43,"completion":125,"start":126,"enrollment":127,"conditions":186,"interventions":187},[86],[21],[44,130,131],{"nctId":74,"briefTitle":75,"status":141,"phases":189,"primaryCompletion":76,"completion":143,"start":144,"enrollment":145,"conditions":190,"interventions":191},[85,86],[21],[44,130,131],{"trials":193,"activeCount":94},[],{"trials":195,"activeCount":94},[],{"intervention":62,"totalTrials":12,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":215,"NA":217},{"trials":199,"activeCount":94},[],{"trials":201,"activeCount":94},[],{"trials":203,"activeCount":94},[],{"trials":205,"activeCount":12,"soonestReadout":61},[206],{"nctId":59,"briefTitle":60,"status":104,"phases":207,"primaryCompletion":61,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},[85,86],"2029-03-30","2026-02-26",120,[212],"Chronic Hepatitis D",[62,214],"Bulevirtide",{"trials":216,"activeCount":94},[],{"trials":218,"activeCount":94},[],{"intervention":214,"totalTrials":12,"cells":220},{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":233,"NA":235},{"trials":222,"activeCount":94},[],{"trials":224,"activeCount":94},[],{"trials":226,"activeCount":94},[],{"trials":228,"activeCount":12,"soonestReadout":61},[229],{"nctId":59,"briefTitle":60,"status":104,"phases":230,"primaryCompletion":61,"completion":208,"start":209,"enrollment":210,"conditions":231,"interventions":232},[85,86],[212],[62,214],{"trials":234,"activeCount":94},[],{"trials":236,"activeCount":94},[],{"intervention":139,"totalTrials":12,"cells":238},{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":245,"PHASE4":251,"NA":253},{"trials":240,"activeCount":94},[],{"trials":242,"activeCount":94},[],{"trials":244,"activeCount":94},[],{"trials":246,"activeCount":12,"soonestReadout":57},[247],{"nctId":55,"briefTitle":56,"status":104,"phases":248,"primaryCompletion":57,"completion":134,"start":135,"enrollment":136,"conditions":249,"interventions":250},[86],[21],[44,139],{"trials":252,"activeCount":94},[],{"trials":254,"activeCount":94},[],{"intervention":49,"totalTrials":256,"cells":257},9,{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":273,"PHASE3":304,"PHASE4":340,"NA":342},{"trials":259,"activeCount":94},[],{"trials":261,"activeCount":94},[262],{"nctId":263,"briefTitle":264,"status":265,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT02475317","Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion","COMPLETED",[84],"2015-12-01","2015-06-01",84,[271],"Healthy Volunteers",[49,39],{"trials":274,"activeCount":94},[275,286,295],{"nctId":276,"briefTitle":277,"status":265,"phases":278,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":285},"NCT04524390","Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai",[85],"2023-11-07","2024-02-07","2021-07-08",75,[284],"Biliary Atresia",[49],{"nctId":287,"briefTitle":288,"status":265,"phases":289,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":294},"NCT04168385","MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study",[85],"2024-09-04","2020-01-16",52,[33],[49],{"nctId":296,"briefTitle":297,"status":265,"phases":298,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":303},"NCT04729751","A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).",[85],"2024-12-17","2021-09-09",27,[24,15,33],[49],{"trials":305,"activeCount":12,"soonestReadout":48},[306,315,324,331],{"nctId":307,"briefTitle":308,"status":265,"phases":309,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":314},"NCT04185363","An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)",[86],"2025-04-23","2020-01-08",90,[18],[49],{"nctId":316,"briefTitle":317,"status":318,"phases":319,"primaryCompletion":320,"completion":320,"start":321,"enrollment":94,"conditions":322,"interventions":323},"NCT03353454","A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)","WITHDRAWN",[86],"2020-06-15","2018-10-25",[18],[49],{"nctId":46,"briefTitle":47,"status":141,"phases":325,"primaryCompletion":48,"completion":326,"start":327,"enrollment":312,"conditions":328,"interventions":330},[86],"2027-02","2024-10-14",[329],"Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)",[49],{"nctId":332,"briefTitle":333,"status":265,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":339},"NCT03905330","A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)",[86],"2022-09-01","2019-07-09",93,[18],[49],{"trials":341,"activeCount":94},[],{"trials":343,"activeCount":94},[344],{"nctId":345,"briefTitle":346,"status":347,"phases":348,"conditions":349,"interventions":350},"NCT04530994","A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)","APPROVED_FOR_MARKETING",[],[15],[351],"maralixibat",{"intervention":39,"totalTrials":19,"cells":353},{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":362,"PHASE3":389,"PHASE4":391,"NA":393},{"trials":355,"activeCount":94},[],{"trials":357,"activeCount":94},[358],{"nctId":263,"briefTitle":264,"status":265,"phases":359,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":360,"interventions":361},[84],[271],[49,39],{"trials":363,"activeCount":29,"soonestReadout":38},[364,374,381],{"nctId":365,"briefTitle":366,"status":367,"phases":368,"primaryCompletion":369,"completion":369,"start":370,"enrollment":19,"conditions":371,"interventions":373},"NCT04718961","A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)","TERMINATED",[85],"2022-12-07","2021-01-04",[372],"Intrahepatic Cholestasis of Pregnancy",[39],{"nctId":36,"briefTitle":37,"status":141,"phases":375,"primaryCompletion":38,"completion":53,"start":376,"enrollment":377,"conditions":378,"interventions":380},[85],"2020-12-18",182,[379],"Primary Sclerosing Cholangitis",[39],{"nctId":51,"briefTitle":52,"status":104,"phases":382,"primaryCompletion":53,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":388},[85],"2027-07","2021-09-22",260,[387,31],"Primary Biliary Cholangitis",[39],{"trials":390,"activeCount":94},[],{"trials":392,"activeCount":94},[],{"trials":394,"activeCount":94},[],{"intervention":67,"totalTrials":12,"cells":396},{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":413,"PHASE4":415,"NA":417},{"trials":398,"activeCount":94},[],{"trials":400,"activeCount":94},[],{"trials":402,"activeCount":12,"soonestReadout":66},[403],{"nctId":64,"briefTitle":65,"status":104,"phases":404,"primaryCompletion":66,"completion":66,"start":405,"enrollment":406,"conditions":407,"interventions":409},[85],"2025-11-22",60,[408],"Fragile X Syndrome",[67,410,411,412],"Middle Dose of MRM-3379","High dose of MRM-3379","Low dose of MRM-3379 Open-Label",{"trials":414,"activeCount":94},[],{"trials":416,"activeCount":94},[],{"trials":418,"activeCount":94},[],{"intervention":410,"totalTrials":12,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":431,"PHASE4":433,"NA":435},{"trials":422,"activeCount":94},[],{"trials":424,"activeCount":94},[],{"trials":426,"activeCount":12,"soonestReadout":66},[427],{"nctId":64,"briefTitle":65,"status":104,"phases":428,"primaryCompletion":66,"completion":66,"start":405,"enrollment":406,"conditions":429,"interventions":430},[85],[408],[67,410,411,412],{"trials":432,"activeCount":94},[],{"trials":434,"activeCount":94},[],{"trials":436,"activeCount":94},[],{"intervention":411,"totalTrials":12,"cells":438},{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":449,"PHASE4":451,"NA":453},{"trials":440,"activeCount":94},[],{"trials":442,"activeCount":94},[],{"trials":444,"activeCount":12,"soonestReadout":66},[445],{"nctId":64,"briefTitle":65,"status":104,"phases":446,"primaryCompletion":66,"completion":66,"start":405,"enrollment":406,"conditions":447,"interventions":448},[85],[408],[67,410,411,412],{"trials":450,"activeCount":94},[],{"trials":452,"activeCount":94},[],{"trials":454,"activeCount":94},[],{"intervention":412,"totalTrials":12,"cells":456},{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":467,"PHASE4":469,"NA":471},{"trials":458,"activeCount":94},[],{"trials":460,"activeCount":94},[],{"trials":462,"activeCount":12,"soonestReadout":66},[463],{"nctId":64,"briefTitle":65,"status":104,"phases":464,"primaryCompletion":66,"completion":66,"start":405,"enrollment":406,"conditions":465,"interventions":466},[85],[408],[67,410,411,412],{"trials":468,"activeCount":94},[],{"trials":470,"activeCount":94},[],{"trials":472,"activeCount":94},[],{"intervention":474,"totalTrials":12,"cells":475},"Cholbam",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":486},{"trials":477,"activeCount":94},[],{"trials":479,"activeCount":94},[],{"trials":481,"activeCount":94},[],{"trials":483,"activeCount":94},[],{"trials":485,"activeCount":94},[],{"trials":487,"activeCount":12,"soonestReadout":492},[488],{"nctId":489,"briefTitle":490,"status":141,"phases":491,"primaryCompletion":492,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT03115086","The REPLACE Registry for Cholbam® (Cholic Acid)",[],"2038-07","2039-07","2017-07-10",55,[497],"Bile Acid Synthesis Disorders",[474],{"intervention":72,"totalTrials":12,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":502,"activeCount":94},[],{"trials":504,"activeCount":94},[],{"trials":506,"activeCount":94},[],{"trials":508,"activeCount":94},[],{"trials":510,"activeCount":94},[],{"trials":512,"activeCount":12,"soonestReadout":71},[513],{"nctId":69,"briefTitle":70,"status":104,"phases":514,"primaryCompletion":71,"completion":515,"start":516,"enrollment":517,"conditions":518,"interventions":519},[],"2030-09-20","2023-09-21",70,[15,24],[72,72],{"intervention":521,"totalTrials":29,"cells":522},"Cholic acid",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":552,"NA":554},{"trials":524,"activeCount":94},[],{"trials":526,"activeCount":94},[],{"trials":528,"activeCount":94},[],{"trials":530,"activeCount":94},[531,541],{"nctId":532,"briefTitle":533,"status":265,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT01115582","Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis",[86],"2010-08","2010-04",16,[539],"Inborn Errors of Bile Acid Synthesis",[521],{"nctId":542,"briefTitle":543,"status":265,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":550},"NCT01438411","Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis",[86],"2016-07","2010-01",53,[549],"Bile Acid Synthesis Defect",[551],"Cholic Acid",{"trials":553,"activeCount":94},[],{"trials":555,"activeCount":94},[],{"intervention":557,"totalTrials":12,"cells":558},"Blinded CDCA 250 mg TID",{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":565,"PHASE4":581,"NA":583},{"trials":560,"activeCount":94},[],{"trials":562,"activeCount":94},[],{"trials":564,"activeCount":94},[],{"trials":566,"activeCount":94},[567],{"nctId":568,"briefTitle":569,"status":265,"phases":570,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":575,"interventions":577},"NCT04270682","Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)",[86],"2023-07-13","2023-10-04","2020-01-31",19,[576],"CTX",[557,578,579,580],"Open-Label CDCA 250 mg TID","Rescue Medication CDCA 250 mg TID","CDCA Weight-Based Dose TID",{"trials":582,"activeCount":94},[],{"trials":584,"activeCount":94},[],{"intervention":578,"totalTrials":12,"cells":586},{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":599,"NA":601},{"trials":588,"activeCount":94},[],{"trials":590,"activeCount":94},[],{"trials":592,"activeCount":94},[],{"trials":594,"activeCount":94},[595],{"nctId":568,"briefTitle":569,"status":265,"phases":596,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":597,"interventions":598},[86],[576],[557,578,579,580],{"trials":600,"activeCount":94},[],{"trials":602,"activeCount":94},[],{"intervention":579,"totalTrials":12,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":617,"NA":619},{"trials":606,"activeCount":94},[],{"trials":608,"activeCount":94},[],{"trials":610,"activeCount":94},[],{"trials":612,"activeCount":94},[613],{"nctId":568,"briefTitle":569,"status":265,"phases":614,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":615,"interventions":616},[86],[576],[557,578,579,580],{"trials":618,"activeCount":94},[],{"trials":620,"activeCount":94},[],{"intervention":580,"totalTrials":12,"cells":622},{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":635,"NA":637},{"trials":624,"activeCount":94},[],{"trials":626,"activeCount":94},[],{"trials":628,"activeCount":94},[],{"trials":630,"activeCount":94},[631],{"nctId":568,"briefTitle":569,"status":265,"phases":632,"primaryCompletion":571,"completion":572,"start":573,"enrollment":574,"conditions":633,"interventions":634},[86],[576],[557,578,579,580],{"trials":636,"activeCount":94},[],{"trials":638,"activeCount":94},[],{"intervention":640,"totalTrials":12,"cells":641},"Cholic Acids",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":664,"NA":666},{"trials":643,"activeCount":94},[],{"trials":645,"activeCount":94},[],{"trials":647,"activeCount":94},[],{"trials":649,"activeCount":94},[650],{"nctId":651,"briefTitle":652,"status":265,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":663},"NCT00007020","Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid",[86],"2009-12","1992-01",85,[658,659,660,661,662],"Infantile Refsum's Disease","Zellweger Syndrome","Adrenoleukodystrophy","Peroxisomal Disorders","Cholestasis",[640],{"trials":665,"activeCount":94},[],{"trials":667,"activeCount":94},[],{"intervention":669,"totalTrials":256,"cells":670},"LUM001",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":757,"PHASE4":759,"NA":761},{"trials":672,"activeCount":94},[],{"trials":674,"activeCount":94},[],{"trials":676,"activeCount":94},[677,686,696,705,714,723,731,740,749],{"nctId":678,"briefTitle":679,"status":318,"phases":680,"primaryCompletion":681,"completion":682,"start":683,"enrollment":94,"conditions":684,"interventions":685},"NCT02321306","An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis",[85],"2017-12","2018-03","2015-05",[28],[669],{"nctId":687,"briefTitle":688,"status":265,"phases":689,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":695},"NCT01903460","Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome",[85],"2015-02","2015-03","2013-08",20,[15],[669],{"nctId":697,"briefTitle":698,"status":265,"phases":699,"primaryCompletion":700,"completion":700,"start":692,"enrollment":701,"conditions":702,"interventions":703},"NCT01904058","Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis",[85],"2015-04",66,[31,28],[669,704],"Ursodeoxycholic Acid",{"nctId":706,"briefTitle":707,"status":265,"phases":708,"primaryCompletion":709,"completion":709,"start":710,"enrollment":301,"conditions":711,"interventions":713},"NCT02061540","Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis",[85],"2016-02","2014-03",[712],"Primary Sclerosing Cholangitis (PSC)",[669],{"nctId":715,"briefTitle":716,"status":265,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":722},"NCT02117713","An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome",[85],"2020-06-01","2015-03-16",34,[15],[669],{"nctId":724,"briefTitle":725,"status":265,"phases":726,"primaryCompletion":727,"completion":727,"start":728,"enrollment":574,"conditions":729,"interventions":730},"NCT02047318","An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)",[85],"2020-06-17","2013-12-20",[15],[669],{"nctId":732,"briefTitle":733,"status":265,"phases":734,"primaryCompletion":735,"completion":735,"start":736,"enrollment":737,"conditions":738,"interventions":739},"NCT02160782","Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)",[85],"2020-05-28","2014-10-28",31,[15],[669],{"nctId":741,"briefTitle":742,"status":265,"phases":743,"primaryCompletion":744,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":748},"NCT02057718","Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis",[85],"2020-05-08","2014-03-01",33,[18],[669],{"nctId":750,"briefTitle":751,"status":265,"phases":752,"primaryCompletion":753,"completion":753,"start":754,"enrollment":6,"conditions":755,"interventions":756},"NCT02057692","Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome",[85],"2016-11-16","2014-11-24",[15],[669],{"trials":758,"activeCount":94},[],{"trials":760,"activeCount":94},[],{"trials":762,"activeCount":94},[],{"intervention":764,"totalTrials":22,"cells":765},"SHP626",{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":786,"PHASE3":797,"PHASE4":799,"NA":801},{"trials":767,"activeCount":94},[],{"trials":769,"activeCount":94},[770,778],{"nctId":771,"briefTitle":772,"status":265,"phases":773,"primaryCompletion":774,"completion":774,"start":775,"enrollment":269,"conditions":776,"interventions":777},"NCT02287779","Safety and Tolerability Study of SHP626 in Overweight and Obese Adults",[84],"2015-06-19","2015-01-19",[26],[764],{"nctId":779,"briefTitle":780,"status":265,"phases":781,"primaryCompletion":782,"completion":782,"start":782,"enrollment":783,"conditions":784,"interventions":785},"NCT02571192","A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose",[84],"2015-10-01",8,[26],[764],{"trials":787,"activeCount":94},[788],{"nctId":789,"briefTitle":790,"status":367,"phases":791,"primaryCompletion":792,"completion":792,"start":793,"enrollment":794,"conditions":795,"interventions":796},"NCT02787304","Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)",[85],"2018-07-27","2016-10-24",197,[26],[764],{"trials":798,"activeCount":94},[],{"trials":800,"activeCount":94},[],{"trials":802,"activeCount":94},[],{"intervention":704,"totalTrials":12,"cells":804},{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":815,"PHASE4":817,"NA":819},{"trials":806,"activeCount":94},[],{"trials":808,"activeCount":94},[],{"trials":810,"activeCount":94},[811],{"nctId":697,"briefTitle":698,"status":265,"phases":812,"primaryCompletion":700,"completion":700,"start":692,"enrollment":701,"conditions":813,"interventions":814},[85],[31,28],[669,704],{"trials":816,"activeCount":94},[],{"trials":818,"activeCount":94},[],{"trials":820,"activeCount":94},[]]